Zynex (NasdaqGS:ZYXI) Q3 2025 Earnings Call November 18, 2025 09:00 AM ET Company ParticipantsStephen Dyson - CEOVikram Bajaj - CFOOperatorGood morning, ladies and gentlemen, and thank you for standing by. Welcome to the Zynex third quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. As a reminder, this conference is being recorded. I would now like to turn the conference over to Vikram Bajaj, Chief Financial Officer of Zynex. Please go ahead.Vikram BajajThank yo ...

Financial Data and Key Metrics Changes - Net revenue for Q3 2025 was $13.4 million, a significant decline from $50 million in Q3 2024, primarily due to TRICARE payment suspension and a $2.8 million reduction in revenue related to payments received during the suspension period [11][12] - Gross profit in Q3 2025 was $8.1 million, or 60% of revenue, compared to $39.8 million, or 80% of revenue, in Q3 2024 [12] - Net loss for Q3 2025 was $42.9 million, or $1.42 per share, compared to a net income of $2.4 million in Q3 2024 [14] Business Line Data and Key Metrics Changes - Device revenue was $7.1 million, while supplies revenue was $6.3 million in Q3 2025, reflecting the overall decline in net revenue [11] - Sales and marketing expenses decreased by 54% to $9.5 million in Q3 2025, primarily due to headcount reduction [12] Market Data and Key Metrics Changes - The decline in revenue was attributed to changes in payers' claim submission and review practices, resulting in denials and payment delays [11] - Workforce reductions in Q1 and Q2 negatively impacted device orders and new patient onboarding, contributing to the overall revenue decline [12] Company Strategy and Development Direction - The company is focused on a three-part strategy: addressing government agency concerns, managing near-term debt obligations, and improving revenue and cash flow performance [5][6] - A new resupply order fulfillment policy was implemented to enhance patient engagement and compliance [6][7] - The company is actively seeking to raise new capital to fund operations and address the maturity of $60 million in convertible senior notes due in May 2026 [6][8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about progress in addressing compliance and integrity issues, although uncertainty remains regarding TRICARE reinstatement and ongoing investigations [6][10] - Early signs of success were noted in improving sales force productivity and order volumes, despite a reduced sales force [9][10] Other Important Information - The company had $13.3 million in cash and cash equivalents as of September 30, 2025, and experienced a negative cash flow of $6.3 million during the quarter [7][14] - A non-cash asset impairment charge of $30.7 million was recorded, primarily related to goodwill and certain fixed assets [14][15] Q&A Session Summary - No specific questions or answers were documented in the provided content, indicating that the call concluded without a Q&A segment [17]